Breast implant-associated anaplastic large cell lymphoma: sensitivity, specificity, and findings of imaging studies in 44 patients Beatriz E. AdradaRoberto N. MirandaWei Yang Review 30 July 2014 Pages: 1 - 14
The additional cancer yield of clinical breast examination in screening of women at hereditary increased risk of breast cancer: a systematic review Toni RoekeAnnelotte C. M. van BommelRob A. E. M. Tollenaar Review 08 August 2014 Pages: 15 - 23
ERK1/2 is related to oestrogen receptor and predicts outcome in hormone-treated breast cancer Dena A. JerjeesM. AlabdullahEmad A. Rakha Preclinical study 02 August 2014 Pages: 25 - 37
MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer Jae Moon GwakHyun Jeong KimSo Yeon Park Preclinical study 03 August 2014 Pages: 39 - 49
ESPL1 is a candidate oncogene of luminal B breast cancers Pascal FinettiArnaud GuilleFrançois Bertucci Preclinical study 03 August 2014 Pages: 51 - 59
Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial Volkmar MüllerStephan GadeHeidi Schwarzenbach Preclinical study 03 August 2014 Pages: 61 - 68
Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic mice Eun-Young GilUk-Hyun JoKyong Hwa Park Preclinical study 08 August 2014 Pages: 69 - 80
Targeted radiosensitization with PARP1 inhibition: optimization of therapy and identification of biomarkers of response in breast cancer Felix Y. FengCorey SpeersLori J. Pierce Preclinical study 08 August 2014 Pages: 81 - 94
Survival outcome and reduction rate of Ki-67 between pre- and post-neoadjuvant chemotherapy in breast cancer patients with non-pCR Nobuaki MatsubaraHirofumi MukaiNoriaki Wada Clinical trial 09 August 2014 Pages: 95 - 102
Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis Naoki NiikuraNaoki HayashiHiroji Iwata Clinical trial 09 August 2014 Pages: 103 - 112
Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study Vasily GiannakeasJan LubinskiSteven A. Narod Epidemiology 01 August 2014 Pages: 113 - 118
Development and validation of a new algorithm for the reclassification of genetic variants identified in the BRCA1 and BRCA2 genes Dmitry PrussBrian MorrisKarla R. Bowles Epidemiology 02 August 2014 Pages: 119 - 132
RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families Ana BlancoSara Gutiérrez-EnríquezAna Vega Epidemiology 03 August 2014 Pages: 133 - 143
Genetic variation in the JAK/STAT/SOCS signaling pathway influences breast cancer-specific mortality through interaction with cigarette smoking and use of aspirin/NSAIDs: the Breast Cancer Health Disparities Study Martha L. SlatteryAbbie LundgreenEsther M. John Epidemiology 08 August 2014 Pages: 145 - 158
Metabolic syndrome and breast cancer prognosis Franco BerrinoAnna VillariniPatrizia Pasanisi Epidemiology 08 August 2014 Pages: 159 - 165
Trends in breast cancer incidence and mortality in France 1990–2008 F. MoliniéA. VanierB. Tretarre Epidemiology 09 August 2014 Pages: 167 - 175
Impact of hospital volume on breast cancer outcome: a population-based study in the Netherlands Sabine SieslingVivianne C. G. Tjan-HeijnenOtto Visser Epidemiology 09 August 2014 Pages: 177 - 184
Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status Aleix PratCristina CruzJudith Balmaña Brief Report Open access 22 July 2014 Pages: 185 - 191
Ghrelin and des-acyl ghrelin inhibit aromatase expression and activity in human adipose stromal cells: suppression of cAMP as a possible mechanism Maria M. DocantoFangyuan YangKristy A. Brown Brief Report 24 July 2014 Pages: 193 - 201
RETRACTED ARTICLE: Suppression of the xCT–CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin Feng WangYong Yang Brief Report 02 August 2014 Pages: 203 - 210
Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer L. M. ArthurA. K. TurnbullJ. M. Dixon Brief Report 09 August 2014 Pages: 211 - 219
Haste makes waste: Are the data regarding TARGIT-A IORT ready for prime time? Orit Kaidar-PersonPhilip PoortmansJohn Yarnold Letter to the Editor 22 July 2014 Pages: 221 - 222
Haste makes waste, but lack of urgency is opportunity lost Laura EssermanMitchell HayesMichael Alvarado Rebuttal Letter 26 July 2014 Pages: 223 - 224
Erratum to: Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort Agnès FournierSylvie MesrineNathalie Chabbert-Buffet Erratum 03 August 2014 Pages: 225 - 225